State-of-the-Art PaperCardiovascular Risk Assessment of the Liver Transplant Candidate
Under an Elsevier user license
open archive
Key Words
coronary artery disease
end-stage liver disease
liver transplant
Abbreviations and Acronyms
CAD
coronary artery disease
CT
computed tomography
DM
diabetes mellitus
DSE
dobutamine stress echocardiography
ESLD
end-stage liver disease
HPS
hepatopulmonary syndrome
LT
liver transplantation
LVOTO
left ventricular outflow tract obstruction
MELD
model for end-stage liver disease
mPAP
mean pulmonary arterial pressure
NPV
negative predictive value
PFO
patent foramen ovale
POPH
portopulmonary hypertension
QTc
corrected QT interval
SPECT
single-positron emission computed tomography
TTE
transthoracic echocardiography
Cited by (0)
Dr. Gheorghiade is a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma AG, CorThera Inc., Cytokinetics Inc., DebioPharm S.A., Errekappa Terapeuitici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma AG, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, and Solvay Pharmaceuticals. All other authors have reported that they have no relationships to disclose.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.